Literature DB >> 19790257

Structural aspects of therapeutic enzymes to treat metabolic disorders.

Tse Siang Kang1, Raymond C Stevens.   

Abstract

Protein therapeutics represents a niche subset of pharmacological agents that is rapidly gaining importance in medicine. In addition to the exceptional specificity that is characteristic of protein therapeutics, several classes of proteins have also been effectively utilized for treatment of conditions that would otherwise lack effective pharmacotherapeutic options. A particularly striking class of protein therapeutics is exogenous enzymes administered for replacement therapy in patients afflicted with metabolic disorders. To date, at least 11 enzymes have either been approved for use, or are in clinical trials for the treatment of selected inherited metabolic disorders. With the recent advancement in structural biology, a significantly larger amount of structural information for several of these enzymes is now available. This article is an overview of the correlation between structural perturbations of these enzymes with the clinical presentation of the respective metabolic conditions, as well as a discussion of the relevant structural modification strategies engaged in improving these enzymes for replacement therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19790257     DOI: 10.1002/humu.21111

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

Review 1.  High-throughput structural biology of metabolic enzymes and its impact on human diseases.

Authors:  Wyatt W Yue; Udo Oppermann
Journal:  J Inherit Metab Dis       Date:  2011-02-22       Impact factor: 4.982

2.  Crystallization, X-ray diffraction analysis and SIRAS phasing of human α-L-iduronidase.

Authors:  Nobuo Maita; Hisaaki Taniguchi; Hitoshi Sakuraba
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-10-30

3.  Membrane anchors effectively traffic recombinant human glucocerebrosidase to the protein storage vacuole of Arabidopsis seeds but do not adequately control N-glycan maturation.

Authors:  Xu He; Jason D Galpin; Yansong Miao; Liwen Jiang; Gregory A Grabowski; Allison R Kermode
Journal:  Plant Cell Rep       Date:  2014-09-04       Impact factor: 4.570

4.  Human α-L-iduronidase uses its own N-glycan as a substrate-binding and catalytic module.

Authors:  Nobuo Maita; Takahiro Tsukimura; Takako Taniguchi; Seiji Saito; Kazuki Ohno; Hisaaki Taniguchi; Hitoshi Sakuraba
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

Review 5.  Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.

Authors:  Lefkothea C Papadopoulou; Asterios S Tsiftsoglou
Journal:  Pharm Res       Date:  2011-08-27       Impact factor: 4.200

Review 6.  Harnessing the Potential of Enzymes as Inhaled Therapeutics in Respiratory Tract Diseases: A Review of the Literature.

Authors:  Gilles Vanderstocken; Nicholas L Woolf; Giuseppe Trigiante; Jessica Jackson; Rory McGoldrick
Journal:  Biomedicines       Date:  2022-06-17

Review 7.  Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.

Authors:  Ryan D Geraets; Seung yon Koh; Michelle L Hastings; Tammy Kielian; David A Pearce; Jill M Weimer
Journal:  Orphanet J Rare Dis       Date:  2016-04-16       Impact factor: 4.123

8.  Towards the development of an enzyme replacement therapy for the metabolic disorder propionic acidemia.

Authors:  Mahnaz Darvish-Damavandi; Han Kiat Ho; Tse Siang Kang
Journal:  Mol Genet Metab Rep       Date:  2016-07-27

Review 9.  From structural biology to designing therapy for inborn errors of metabolism.

Authors:  Wyatt W Yue
Journal:  J Inherit Metab Dis       Date:  2016-05-30       Impact factor: 4.982

10.  Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery.

Authors:  Lorena Sánchez-Sánchez; Alejandro Tapia-Moreno; Karla Juarez-Moreno; Dustin P Patterson; Ruben D Cadena-Nava; Trevor Douglas; Rafael Vazquez-Duhalt
Journal:  J Nanobiotechnology       Date:  2015-10-09       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.